Dornase Alpha for the Treatment of COVID-19

• Status: Recruiting
• Trial end date: 2020-09-25
• Target enrollment: 0
• Participant gender: All

Summary

In this study, the effectiveness of the Dornase Alpha treatment, which is known to reduce the viscosity of respiratory secretions, will be investigated in new diagnosed and severe COVID-19 patients separately.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Acibadem University
• Collaborator: The Scientific and Technological Research Council of Turkey

Criteria

Inclusion Criteria:

• Being 18 or older

• Approving the Informed Consent Form

• Being diagnosed with COVID-19 with PCR and / or radiological clinical findings

• Hospitalization indication according to Ministry of Health criteria

Exclusion Criteria:

• Pregnant and / or breastfeeding women.

• Any known allergy to Dornase Alpha

• Being involved in another drug study

• Previously diagnosed with chronic lung disease